Moderator note: This thread has been getting great engagement. Please remember to cite sources when making clinical claims.
No issues to report — carry on. 👍
Slightly tangential to 2026 payer coverage but amsterdam_pete reminded me — what is the latest on the oral formulations?
I know it is not exactly on-topic but it seems related enough to ask here rather than starting a new thread. Apologies if this has been covered — I did search first.
+1 to maria_elpaso. Especially the point about "Follow-up question: did you change anyth..." — I have seen the same in my own experience with 2026 payer coverage.
Bookmarked 📌 The 2026 payer coverage info in this thread is essential. Coming back to this for sure.
Relevant to 2026 payer coverage update — here is my latest bloodwork comparison:
Key improvements: A1C 7.6% → 5.5%, triglycerides 241 → 111 mg/dL, hsCRP 8.0 → 1.1 mg/L. All on tirzepatide for 9 months.
The inflammatory marker drop is what impresses me most. Consistent with the SELECT trial's cardiovascular findings.